Spirometry. COPD cannot be diagnosed reliably on clinical features or chest x-ray findings alone. The diagnosis of COPD requires spirometry, as it is the most reproducible and objective measurement of airflow limitation. Pre-and post-bronchodilator spirometry should be performed using techniques that meet published standards. COPD is characterised by airflow limitation that is not fully reversible (post-bronchodilator FEV 1 /FVC [forced vital capacity] ratio < 0.7, and FEV 1 < 80% predicted). With spirometry, there is some risk of overdiagnosis in older people or underdiagnosis in younger people, especially when the FEV 1 /FVC ratio is close to 0.7, so borderline results should be interpreted with caution. Many patients with COPD have some reversibility of airflow limitation with bronchodilators. An FEV 1 increase of 12% and 200 mL constitutes a positive bronchodilator response. An FEV 1 increase of > 400 mL suggests underlying asthma, or coexisting asthma and COPD. 5 Investigations. Investigations to confirm or exclude other conditions with a similar presentation to COPD (eg, bronchiectasis, lung cancer, heart failure and anaemia) include chest x-ray, haematology and biochemistry, complex lung function tests, exercise stress testing, and electrocardiography and echocardiography. Investigations to assess gas exchange include oximetry and arterial blood gases (if the arterial oxygen saturation measured by pulse oximeter [SpO 2 ] is < 92% when stable or if hypercapnia is suspected).
Severity. Assessing the severity of COPD should take into account lung function, history of exacerbations and comorbid conditions (Box 1). The COPD Assessment Test (CAT) can determine the impact of COPD symptoms on wellbeing and daily life. 6 
O: Optimise function
Non-pharmacological strategies. There is strong evidence for the benefits of pulmonary rehabilitation that involves supervised exercise training alone or in conjunction with patient education or other non-pharmacological interventions (eg, behaviour change, nutritional intervention and psychosocial support) (Box 2). Programs can be provided in hospital outpatient departments or in the community (ie, health care and non-health care facilities, or home settings). [7] [8] [9] Benefits are evident both in those with stable COPD and in individuals who commence rehabilitation after an exacerbation. 7, 8, 10 In the absence of instruction from a specialist exercise professional (eg, physiotherapist or exercise physiologist), individuals with COPD should be encouraged to be physically active (Box 2), as inactivity is associated with increased mortality and exacerbations. 12 Pharmacological strategies. Pharmacological therapies aim to reduce symptoms, prevent exacerbations and improve health status, by targeting the pathophysiology of COPD. It is recommended that a stepwise approach to pharmacotherapy be used, until adequate control is achieved (Box 1).
Bronchodilators. Short-acting bronchodilators (b 2 -agonists) are used as needed for short term symptom relief. If these are insufficient, then long-acting bronchodilators should be added. Long-acting muscarinic antagonists (LAMAs) and long-acting b 2 -agonists (LABAs) reduce breathlessness, improve quality of life, and decrease the risk of exacerbations. 13, 14 If breathlessness or exacerbations persist with 1 Stepwise management of stable chronic obstructive pulmonary disease (COPD)* Anti-inflammatory agents. An inhaled corticosteroid/LABA (ICS/LABA) combination inhaler may be considered in cases of more severe COPD (FEV 1 < 50% predicted, with a history of repeated exacerbations), although ICS may increase the risk of pneumonia. 16 While combination LAMA/LABA inhalers appear to be more beneficial than ICS/LABA inhalers in reducing exacerbations, 17 the use of an ICS/LABA inhaler together with a LAMA inhaler remains an option for patients with moderate to severe COPD who require additional treatment. 18 Further studies of triple therapy combination inhalers are awaited.
Inhaler technique. A lack of proficiency with inhaler technique continues to be common, with studies reporting handling errors in 50e100% of patients. 19 These reports are concerning, as poor technique is associated with worse outcome. 20 Moreover, inhaler device polypharmacy is an increasing problem, and with an increment in the number of different devices used, there is an associated increase in error rate. 21 At initiation of therapy, education involving instruction, visual demonstration and patient observation is recommended. The treatment choice should consider the patient's ability to use the device proficiently. Once commenced on inhaler therapy, the technique should be reviewed and reinforced regularly. The current inhaled medicines for COPD are shown in the online Appendix, Figure 1 .
Comorbidities. COPD is associated with many comorbidities. 22, 23 Anxiety and depression are major contributors to hospital bed usage and readmissions, and should be optimally managed. Mortality from COPD is more associated with cardiac events than respiratory failure, 24 and the importance of avoiding prolonged overuse of b 2 -agonists is becoming increasingly recognised. 25 Osteoporotic fractures are a common problem in COPD due to risk factors, including smoking, physical inactivity, malnutrition, systemic inflammation, frequent use of corticosteroids, low body mass index, hypogonadism, and vitamin D deficiency. 26 Vertebral fractures can be associated with coughing, leading to considerable pain. Bone mineral density testing is important for prevention and monitoring response to therapy.
Hypoxaemia can lead to pulmonary hypertension and eventually right heart failure, particularly if there is coexisting obstructive sleep apnoea. 27 When suspected clinically, arterial blood gases or a sleep study should be considered, with a view to oxygen therapy or continuous positive airway pressure. COPD increases the risk of developing lung cancer. 28 Lung volume reduction. Lung volume reduction by either surgery or bronchoscopically placed valves is an option for highly selected patients with severe emphysema, hyperinflation and ongoing symptoms despite maximal medical management and pulmonary rehabilitation. Surgery is associated with increased short term mortality but reduced long term mortality, 29 while endobronchial techniques are associated with high short term morbidity (especially pneumothorax) but improved health outcomes at 12 months. 30 Such therapies should only be considered in specialised centres. 31 
P: Prevent deterioration
Smoking cessation. Tobacco smoking is a key risk factor in the development of COPD, and smoking cessation is the most important intervention to slow decline in lung function. People with COPD who continue to smoke often have coexisting anxiety and depression. Smoking cessation advice from health professionals helps to motivate quit attempts and to increase long term quit rates. Hospital admission represents an opportunity to initiate smoking cessation, but support needs to continue after discharge. A comprehensive approach to supporting smoking cessation involves behavioural support and treatment of nicotine dependence. 32 Counselling may be structured using the 5-As strategy:
ask and identify smokers at every health care visit; assess nicotine dependence and the motivation to quit; advise about the risks of smoking and benefits of quitting; assist cessation; and arrange follow-up within one week of the quit date and one month after.
If time is short, advice to quit and referral to the Quitline (13 78 48) is an alternative option. Nicotine dependence may be treated with nicotine replacement therapy, varenicline or bupropion. The most effective forms of pharmacotherapy are either combination nicotine replacement therapy (ie, a patch combined with a rapid-acting form of nicotine replacement therapy) or varenicline. 33 Longer courses of treatment may reduce relapse.
Vaccinations. Inactivated influenza vaccine reduces exacerbations due to influenza in patients with COPD, especially in epidemic years. 34 Adverse effects are mild, local, transient and self-limiting; there is no increase in early exacerbations before immunity has developed. Annual influenza vaccination is highly cost-effective, particularly in more severe COPD cases. 34 Patients aged 50 years who are immunised with polysaccharide pneumococcal vaccine, along with revaccination 5 years later, 35 will have protection against community-acquired pneumonia and a reduced likelihood of COPD exacerbations. 36 When added to annual influenza immunisation, pneumococcal immunisation has additive beneficial effect on COPD exacerbations. 37 Long term oxygen therapy. Correction of severe hypoxaemia improves survival in COPD, and greater benefits are seen in patients who use supplemental oxygen for longer periods. 38 At least 18 hours per day is generally recommended for patients with an arterial partial pressure of oxygen (PaO 2 ) of 55 mmHg, or 59 mmHg in the presence of pulmonary hypertension, right heart failure or polycythaemia. 38 There is no indication for continuous oxygen therapy in patients with moderate hypoxaemia (SpO 2 89e93%). 39 Ambulatory oxygen may be of occasional benefit in individuals who desaturate with exertion. Assessment should evaluate improvement in dyspnoea and exercise capacity on a standardised exercise test. As the relationship between demonstrated benefit during a clinic or laboratory assessment and long term benefit is unclear, review with assessment of oxygen usage, determination of benefit and need for continued use are important.
Palliative care services. In patients with advanced COPD, palliative care services improve symptom control and manage psychosocial and spiritual concerns. 40 Supportive care principles are important for end-of-life care. Discussion regarding advanced care directives should be undertaken as part of usual management at a suitable time in the disease course.
D: Develop a plan of care
Chronic disease management and self-management. Chronic disease management can be defined as comprehensive strategies for improving overall health status and reducing health care costs. Self-management support is the systematic provision of education and supportive interventions by health care staff to increase patients' skills and confidence in managing their health problems. 41 Self-management programs frequently include emotional support, problem solving and decision making, development of therapeutic partnerships, goal setting and action planning. In 
Manage exacerbations
A COPD exacerbation is characterised by a change in the patient's baseline dyspnoea, cough or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication or hospital admission
III-2 Strong
Early diagnosis and treatment of exacerbations may prevent hospital admission and delay COPD progression
Multidisciplinary care may assist home management of some patients with an exacerbation I Weak COPD, interventions focus on exacerbation management, adherence to pharmacological and non-pharmacological strategies, smoking cessation, physical activity, exercise and management strategies for psychological dysfunction.
Self-management programs in COPD consistently lead to improved outcomes, particularly health status. 42, 43 However, the impact on health care use has been inconsistent. Some systematic reviews have shown lower risk of respiratory-related hospitalisation 44 and urgent health care use, 45 whereas others have found no reduction in hospitalisations. 42 As the randomised controlled trials have been heterogeneous, firm recommendations about the type and duration of self-management program, as well as subgroups most likely to respond, are not yet possible.
Multidisciplinary team. Delivery of COPD self-management programs requires a multidisciplinary team. Key disciplines involved in COPD management include the general practitioner, specialist physician (Box 3), respiratory and primary care nurses, physiotherapists, psychologists, nutritionists, occupational therapists, social workers and pharmacists.
COPD action plan. Exacerbation avoidance and management in COPD is an important goal. A Cochrane review of seven randomised controlled trials concluded that COPD exacerbation action plans that are prescribed and delivered within a single short educational program, with ongoing support directed at the use of the action plan, reduce in-hospital health care use and increase the initiation of corticosteroids and antibiotics for COPD exacerbations. 46 Hence, COPD action plans are recommended as part of COPD self-management.
X: Manage exacerbations
Manage exacerbations. A COPD exacerbation is characterised by an increase in dyspnoea, cough and sputum, is acute in onset and typically warrants a change in medication or hospital admission. A past history of exacerbations is the best predictor of future exacerbations, and patients with more severe COPD (based on FEV 1 ) are more likely to exacerbate. 47 Hospitalisation for an exacerbation of COPD is a sentinel event (Box 3). Twelve-month mortality rates following a hospitalisation for COPD are about 25%. 48 Triggers for exacerbations include viral or bacterial respiratory infection, left ventricular failure, psychosocial stressors and air pollution. Pulmonary embolism should be considered in patients presenting with an exacerbation of COPD when signs of an infection are absent. 49 Early recognition and management of exacerbations improve recovery and quality of life, reduce hospitalisation and may prevent progressive functional deterioration. 50 A COPD action plan serves to help patients and carers recognise and respond to the early signs of an exacerbation and prevents hospitalisation. 46 Pharmacological management of exacerbations. Increased doses of salbutamol (short-acting bronchodilator), 4e8 puffs (400e800 mg) via a metered dose inhaler and spacer every 3e4 hours, should be used. This formulation is as effective as via nebuliser. 51 A morning dose of oral prednisolone 30e50 mg should be taken for 5 days; tapering the dose is rarely necessary. 52 Intravenous corticosteroids are not superior to oral corticosteroids. 53 Exacerbations with signs and symptoms of infection (increased volume and change in colour of sputum or fever) benefit from antibiotics. First-line agents include oral amoxicillin or doxycycline for 5 days. 54 In patients requiring admission or when pneumonia is suspected, a chest x-ray should be performed and pneumonia treatment should follow guidelines. 54 Discharge planning. Early hospital discharge may be appropriate with the use of a hospital in the home program. Such programs facilitate early discharge within 48 hours and allow patients to be managed at home with involvement of multidisciplinary teams assisting general practitioners. These programs lead to a reduction in readmission rates with no increase in mortality. 55 Oxygen therapy and non-invasive ventilation. If hypoxaemia is present, the SpO 2 target range should be 88e92%. This can usually be achieved by the administration of oxygen via nasal cannula at a rate of 0.5e2 L/min. 56 High flow oxygen can significantly increase mortality in patients with COPD. 57 It is important that patients with COPD presenting to hospital with a severe exacerbation be assessed with an arterial blood gas measurement. Patients with hypercapnic respiratory failure (arterial partial pressure of carbon dioxide [PaCO 2 ] > 45 mmHg and blood pH < 7.35) should be treated in hospital with non-invasive ventilation, which reduces mortality and need for endotracheal intubation and shortens hospital length of stay. 58 Post-discharge pulmonary rehabilitation. The discharge plan should be promptly shared with the primary care team; patients should receive self-management education. As pulmonary rehabilitation reduces readmission rates and improves quality of life, 59 the patient should be referred to pulmonary rehabilitation as soon as the acute instability has resolved.
Evidence base and resources
For full details of the evidence base, references and quarterly updates, please refer to the COPD-X guidelines at http:/ /copdx.org.au. The key changes since the publication of the 2006 clinical practice update in the Journal 3 are summarised in the online Appendix, table 1. COPD resources are available from Lung Foundation Australia (www.lungfoundation.com.au), including the COPD-X Concise Guide for Primary Care, which contains clinical recommendations (Box 4) and practice tips for busy health professionals in primary care.
